Novo Nordisk A/S (NVO) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects strong financial performance with an 18% sales growth and 20% operating profit increase. The company's strategic initiatives, such as partnerships and market expansions, are promising. While there are some uncertainties in litigation and pricing strategies, management's confidence in growth, particularly in China, and the launch of new products like oral Wegovy, supports a positive outlook. The guidance suggests continued strong performance, and there's optimism in overcoming challenges like LOE impacts. Overall, the sentiment is positive, with potential for stock price appreciation.
Key Financial Performance
Sales Growth 18% sales growth in the first 6 months of 2025 compared to the same period in 2024. This growth was driven by both U.S. operations (17% growth) and international operations (19% growth). The increase was positively impacted by gross-to-net sales adjustments related to prior years.
Operating Profit Growth 29% operating profit growth in the first 6 months of 2025 compared to the same period in 2024. This was driven by increased sales and a positive product mix, particularly from GLP-1-based treatments.
GLP-1 Sales in Diabetes 10% increase in GLP-1 sales in diabetes in the first 6 months of 2025 compared to the same period in 2024. U.S. operations grew by 9%, and international operations grew by 10%. The growth was driven by the uptake of Ozempic, partially offset by Victoza and Rybelsus.
Obesity Care Sales 58% increase in obesity care sales in the first 6 months of 2025 compared to the same period in 2024. U.S. operations grew by 36%, and international operations grew by 125%. The growth was driven by increased volumes of Wegovy, although partially countered by lower realized prices.
Rare Disease Sales 15% increase in rare disease sales in the first 6 months of 2025 compared to the same period in 2024. U.S. operations grew by 23%, and international operations grew by 10%. Sales of rare endocrine disorder products increased by 49%, driven by Norditropin and Sogroya launch uptake. Red blood disorder sales increased by 6%, driven by NovoSeven and Alhemo.
Gross Margin Decreased to 83.4% in the first 6 months of 2025 compared to 84.9% in 2024. The decrease was mainly due to amortizations and depreciations related to Catalent and costs related to capacity expansions, partially offset by a positive product mix from increased GLP-1 sales.
R&D Costs Decreased by 11% in the first 6 months of 2025 compared to the same period in 2024. The decrease was driven by the impairment loss related to ocedurenone and other intangible assets in 2024, partially offset by increased investments in obesity care and late-stage clinical trials.
Net Profit Increased by 22% in the first 6 months of 2025 compared to the same period in 2024. This was driven by higher operating profit and sales growth.
Free Cash Flow Decreased to DKK 33.6 billion in the first 6 months of 2025 compared to DKK 41.3 billion in the same period in 2024. The reduction was driven by increased capital expenditures, partially offset by higher net cash generated from operating units.
Capital Expenditure Increased to DKK 28.1 billion in the first 6 months of 2025 compared to DKK 18.9 billion in 2024. This was primarily driven by investments in additional capacity for API production and fill/finish capacity for injectable and oral products.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Ozempic: Received a positive opinion by the EMA for the treatment of peripheral arterial disease in people living with Type-2 diabetes.
Amycretin: Announced advancement into Phase III clinical development for weight management.
CagriSema: Initiated a new Phase IIIb trial, REDEFINE 11, lasting 80 weeks to investigate further potential efficacy and safety.
Collaboration with Septerna: Entered an exclusive collaboration and license agreement to discover and develop small molecules for obesity, Type-2 diabetes, and other cardiometabolic diseases.
U.S. Operations: Sales grew by 17%, driven by GLP-1 diabetes care products and obesity care sales. Wegovy sales increased by 37%, but penetration in the cash channel remains low at 10%.
International Operations: Sales grew by 19%, with obesity care sales increasing by 125%. Wegovy sales alone grew by 335% in international markets.
Market Leadership: Novo Nordisk holds a 71% market share in the GLP-1 diabetes and obesity market in international operations.
Sales Growth: Achieved 18% sales growth and 29% operating profit growth in the first half of 2025.
Promotional Activities: Increased investments in promotional activities for Wegovy and Ozempic in both U.S. and international markets.
Capacity Expansion: Invested in additional capacity for API production and fill/finish capacity for injectable and oral products.
Leadership Transition: Maziar Mike Doustdar to take over as President and CEO on August 7, 2025. Martin Lange appointed as Chief Scientific Officer.
R&D Focus: Unified research and development organization to focus on raising the innovation bar within diabetes and obesity.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Lower growth expectations for Wegovy in the U.S. obesity market: The company has revised its sales outlook for 2025 due to lower-than-expected growth for Wegovy in the U.S. obesity market. This is attributed to the continued presence of unsafe and unlawful mass compounding of GLP-1s, which has impacted Wegovy's penetration in the cash channel.
Lower growth expectations for Ozempic in the U.S. GLP-1 diabetes market: Sales growth for Ozempic in the U.S. diabetes market has been revised downward due to slower-than-expected market penetration and competition from compounded GLP-1s.
Lower-than-expected penetration for Wegovy in select international operations (IO) markets: The company has faced challenges in achieving expected penetration levels for Wegovy in certain international markets, which has contributed to the lowered sales outlook.
Unlawful and unsafe mass compounding of GLP-1s in the U.S.: The persistence of unlawful and unsafe mass compounding of GLP-1s has negatively impacted the uptake of branded products like Wegovy, creating a significant challenge for the company.
Periodic supply movements and inventory issues in Region China: GLP-1 diabetes sales in Region China were lower than expected due to wholesaler inventory movements and timing issues, impacting overall sales growth.
Increased capital expenditures and operational costs: The company has reported higher capital expenditures for capacity expansion and increased promotional activities, which have impacted free cash flow and operational efficiency.
Regulatory and market access challenges: The company faces ongoing regulatory hurdles and market access issues, particularly in expanding the obesity and diabetes markets globally.
Competition in the obesity and diabetes markets: Despite being a market leader, Novo Nordisk faces competitive pressures in both the obesity and diabetes markets, which could impact its market share and growth potential.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Sales Growth Outlook: Novo Nordisk has lowered the full-year sales growth outlook for 2025 to 8%-14% at constant exchange rates, driven by lower growth expectations for Wegovy in the U.S. obesity market, Ozempic in the U.S. GLP-1 diabetes market, and Wegovy in select international operations markets.
Operating Profit Growth Outlook: Operating profit growth for 2025 is now expected to be 10%-16% at constant exchange rates, with reported growth in Danish kroner expected to be 5 percentage points lower.
Capital Expenditures: Capital expenditure for 2025 is expected to be around DKK 65 billion, reflecting investments in global supply chain expansion, including capacity for injectable and oral products.
Free Cash Flow: Free cash flow is now expected to be DKK 35 billion to DKK 45 billion, reflecting lower-than-expected sales growth, mainly driven by lower volume growth of GLP-1 treatments in the U.S.
Wegovy Market Penetration: Wegovy penetration in the U.S. cash channel has been lower than expected, with compounded GLP-1s impacting uptake. Novo Nordisk plans to expand direct-to-patient initiatives and telehealth collaborations to improve penetration.
Regulatory Approvals and Product Launches: Novo Nordisk anticipates a regulatory decision regarding the Wegovy MASH indication in Q3 2025 and plans to launch Ozempic in the cash channel later this year. Wegovy has been launched in 35 countries, with further rollouts planned for the second half of 2025.
R&D Milestones: The AMAZE Phase III program for amycretin will start in early 2026, targeting weight loss and obesity-related comorbidities. Novo Nordisk also expects readouts for the EVOKE and EVOKE+ Phase III trials in early Alzheimer's disease by the end of 2025.
Market Expansion: Novo Nordisk aims to expand the diabetes and obesity markets by reaching new patient groups and physician segments, introducing new channels, and reducing barriers to access. The company plans to invest in promotional activities and innovation to address unmet needs.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Interim Dividend: The Board of Directors has decided to pay out an interim dividend of DKK 3.75 per share, an increase of 7% compared to August 2024. The interim dividend will be paid out in August this year.
Shareholder Returns: We have returned DKK 36.5 billion to shareholders, mainly as dividends in the first 6 months of 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the impact of the Wegovy formulary position with CVS on prescription volumes in the U.S., and how many people might switch to Wegovy?
A:Management stated that the CVS formulary conversion is going according to plan and is largely in line with expectations. However, they did not comment on the specific number of lives or the percentage of conversion.
Q:Has Novo initiated any litigation to address the compounding of GLP-1 drugs?
A:Management emphasized that compounding is illegal in the U.S. except for rare circumstances and that APIs being imported are not from approved facilities. They did not comment directly on any specific litigation but mentioned that no legal actions are categorically off the table and that they are in dialogue with the FDA.
Q:Why has there been destocking in China in Q2, and what is the growth outlook given the arrival of generic semaglutide next year?
A:Management explained that the destocking is due to adjustments from large stocks built last year in anticipation of Wegovy launches. They are confident about growth in China due to unmet needs in diabetes and obesity, with plans to expand into Tier 2, 3, and 4 cities and increase investments in their GLP-1 sales force.
Q:What are the go-forward strategy changes for Novo Nordisk?
A:The incoming CEO emphasized a focus on diabetes and obesity, execution, and reallocating resources to growth areas. He mentioned the need to finance opportunities by reviewing the cost base and increasing agility.
Q:What is the contribution of CVS and NovoCare to the recent TRx dynamics for Wegovy?
A:Management stated that the increases in uptake are partly due to CVS and partly due to other commercial efforts, including a new campaign focused on Wegovy's weight loss benefits. They also plan to expand the NovoCare Pharmacy channel and partner with telehealth and other organizations.
Q:What is the impact of LOE (loss of exclusivity) in international operations on group growth next year?
A:Management estimated that the impact of LOE in specific international markets on group growth next year would be in the low single digits of group sales.
Q:How is Novo positioned in terms of capacity for accelerating international operations and launching oral semaglutide for obesity?
A:Management highlighted that Wegovy's capacity in international operations has increased 4x year-to-date, with launches in 35 markets. They expect to launch oral semaglutide for obesity in the U.S. next year without supply restrictions.
Q:What is the rationale for discontinuing Zalfermin development, and does Novo still have interest in the FGF21 target?
A:Management stated that Zalfermin did not show substantial differentiation from semaglutide in efficacy. They are not necessarily done with the FGF21 biology but found semaglutide to be difficult to beat in this space.
Q:What are the pricing expectations for Wegovy and Ozempic in the second half of the year and into 2026?
A:Management indicated that price erosion for Wegovy is more skewed towards the second half of the year due to channel mix and efforts to reduce access friction. They emphasized disciplined and thoughtful pricing strategies.
Q:What is Novo's perspective on the SURPASS-CVOT trial results for tirzepatide?
A:Management noted that tirzepatide did not demonstrate a benefit over dulaglutide in CV risk reduction, while semaglutide has shown a 26% CV risk reduction. They emphasized that semaglutide stands out in the incretin space for CV benefit.
Q:What are Novo's long-term thoughts on CapEx and cash flow development?
A:Management stated that they are close to the peak of CapEx spending, with major projects nearing completion. Maintenance CapEx is expected to be around 5% of sales in the long term, but current investments are aligned with growth opportunities.
Q:How will the oral Wegovy launch in the U.S. impact the cash channel?
A:Management plans to launch oral Wegovy as close to approval as possible and sees the cash channel as a long-term opportunity for obesity products. They aim to meet patients' access needs through various channels.
Q:What is the development plan for the single-chamber CagriSema device?
A:Management does not expect to need a full Phase III program but will conduct studies to establish clinical equivalence. The single-chamber device does not require new manufacturing facilities.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers or percentages for the CVS formulary conversion and did not directly comment on specific litigation actions regarding compounding. They also did not provide detailed pricing strategies for Wegovy and Ozempic or elaborate on the exact timing and impact of the oral Wegovy launch in the U.S.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADA
AMAZE
Alhemo
Chief Scientific
EMA
Emil
Executive VP
Formulary
GLP diabetes
GLP product
GLP sale
GLPs
Helfgott Executive
III development
IIa
IO market
International
Member
Phase II
Phase III
Research Division
Rode Head
adjustment
cash channel
collaboration
comorbidities
mass compounding
medicine
obesity market
opinion
penetration cash
people diabetes
potential amycretin
program
region
research development
responsibility
segment
semaglutide
NVO Transcript
Novo Nordisk A/S (NOVO:CA) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call reveals mixed sentiments: strong product uptake and successful launches contrast with challenges like U.S. price erosion and supply limitations. Despite positive product feedback and strategic international expansion, the negative growth outlook for U.S. operations and expected decline in sales and operating profit are concerning. The Q&A highlights potential risks with patent expirations and competition. Overall, the sentiment is balanced with both positive developments and significant challenges, leading to a neutral outlook.
Novo Nordisk A/S (NOVO:CA) Q4 2025 Earnings Call Transcript
Unknown2-5
The earnings call summary indicates a mixed outlook. While there are positive elements such as a 16% increase in Wegovy sales and optimistic guidance for Wegovy pill demand, there are also concerns about declining U.S. sales and significant restructuring costs. The Q&A reveals uncertainties in volume uplift and market dynamics, particularly in the obesity sector. These mixed signals, along with stable but not exceptional financial metrics, suggest a neutral sentiment, expecting minimal stock price movement in the short term.
Novo Nordisk A/S (NVO) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call reveals several concerns: lowered sales and profit growth outlooks, market share loss in the GLP-1 market, and challenges in the U.S. obesity market. Despite some optimistic guidance and strategic initiatives, the lowered growth expectations and uncertainties in regulatory approvals and market dynamics create a negative sentiment, likely leading to a stock price decline of -2% to -8%.
Novo Nordisk A/S (NVO) Q2 2025 Earnings Call Transcript
Positive8-6
The earnings call reflects strong financial performance with an 18% sales growth and 20% operating profit increase. The company's strategic initiatives, such as partnerships and market expansions, are promising. While there are some uncertainties in litigation and pricing strategies, management's confidence in growth, particularly in China, and the launch of new products like oral Wegovy, supports a positive outlook. The guidance suggests continued strong performance, and there's optimism in overcoming challenges like LOE impacts. Overall, the sentiment is positive, with potential for stock price appreciation.
NVO Slides
NVO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
